- Home
- KYMR
as 11-15-2024 4:00pm EST
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 3.0B | IPO Year: | 2020 |
| Target Price: | $51.15 | AVG Volume (30 days): | 415.6K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.89 - $53.27 | Next Earning Date: | 10-31-2024 |
| Revenue: | $87,563,000 | Revenue Growth: | 86.92% |
| Revenue Growth (this year): | -33.02% | Revenue Growth (next year): | 21.47% |
Stock Insider Trading Activity of Kymera Therapeutics Inc. (KYMR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Esposito Pamela | KYMR | Director | Sep 17 '24 | Sell | $48.25 | 13,500 | $651,765.65 | 7,150 | |
| Albers Jeffrey W. | KYMR | Director | Aug 26 '24 | Sell | $49.10 | 5,000 | $245,508.50 | 0 | |
| BAKER BROS. ADVISORS LP | KYMR | Director | Aug 20 '24 | Buy | $46.41 | 1 | $46.41 | 5,516,986 |
Latest Kymera Therapeutics Inc. News
KYMR Breaking Stock News: Dive into KYMR Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
MT Newswires
13 days ago
UBS Adjusts Price Target on Kymera Therapeutics to $74 From $80, Maintains Buy Rating
Simply Wall St.
13 days ago
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report
Simply Wall St.
16 days ago
Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
16 days ago
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
MT Newswires
16 days ago
B. Riley Adjusts Price Target on Kymera Therapeutics to $41 From $36, Maintains Neutral Rating
GuruFocus.com
16 days ago
Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
The Wall Street Journal
17 days ago
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
Compare KYMR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KYMR Kymera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.